Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stronger Firewalls Needed In Continuing Medical Education, Senators Say

This article was originally published in The Gray Sheet

Executive Summary

Senators on the Special Committee on Aging want to strengthen the rules that prevent manufacturers from promoting their commercial interests in the continuing medical education (CME) programs they sponsor

You may also be interested in...



House Reform Bill Addresses Physician Payments, "Misvalued" Services

The House's week-old draft health reform bill was the subject of multiple hearings last week, though several provisions relevant to the device industry in the 850-page effort to remake the U.S. health care system did not get much attention

IOM Report On Conflicts Of Interest Cuts Device Firms Some Slack

A recently released Institute of Medicine 1report on conflicts of interest recognizes that medical device sales reps should, in some cases, have greater access to physicians than drug reps

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel